Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Trial Profile

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 2004 (Primary)
  • Indications Pervasive child development disorders
  • Focus Adverse reactions
  • Sponsors Axial Therapeutics
  • Most Recent Events

    • 14 Feb 2022 According to an Axial Biotherapeutics media release, status changed from active, no longer recruiting to completed.
    • 14 Feb 2022 According to an Axial Biotherapeutics media release, Robert L. Hendren, D.O., professor, psychiatry, Weill Institute for Neurosciences at the University of California, San Francisco, School of Medicine, is the principal investigator for the AB-2004 Phase 2 trial
    • 14 Feb 2022 According to an Axial Biotherapeutics media release, Nature Medicine Publishes Full Results from Axial Therapeutics Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top